VIVES fund | Activity | F4

VIVES fund Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

VIVES Partners participated in Bionyra Pharma's $165M oversubscribed Series A, co-led by Jeito Capital and Sofinnova Partners.

Bionyra Pharma

Bionyra Pharma VIVES fund

vivesfund.comJUN 23, 2026

JUN 23, 2026

Investment

Generare raised €20M to scale its molecular data generation platform for drug discovery.

Generare

Generare VIVES fund

vivesfund.comAPR 2, 2026

APR 2, 2026

Milestone

Novadip enrolled the first pediatric patients in its Phase 3 pivotal trial for NVD003 in congenital pseudarthrosis of the tibia.

Novadip Biosciences

Novadip BiosciencesVIVES fund

vivesfund.comDEC 16, 2025

DEC 16, 2025

Investment

VIVES Partners participated in Nuclidium AG's €84M Series B to advance its copper-based radiopharmaceutical pipeline.

Nuclidium

Nuclidium VIVES fund

vivesfund.comJUL 10, 2025

JUL 10, 2025

Milestone

Novadip and Cliniques universitaires Saint-Luc announced positive compassionate-use results for NVD003 in four pediatric patients.

Novadip Biosciences

Novadip BiosciencesVIVES fund

vivesfund.comJUL 1, 2025

JUL 1, 2025

Exit

Portfolio company The Akkermansia Company was acquired by Danone.

The Akkermansia Company

The Akkermansia Company VIVES fund

vivesfund.comJUN 25, 2025

JUN 25, 2025

Milestone

Novadip received RMAT designation for NVD003, its regenerative treatment for congenital pseudarthrosis of the tibia.

Novadip Biosciences

Novadip BiosciencesVIVES fund

vivesfund.comJUN 24, 2025

JUN 24, 2025

Investment

BiocSol raised an additional €4.4M, reaching €10M total raised, to develop sustainable crop-protection biosolutions.

BiocSol

BiocSolVIVES fund

vivesfund.comFEB 14, 2025

FEB 14, 2025

Milestone

Novadip shared positive 12-month Phase 1b/2a trial results for NVDX3 in trauma, with 100% bone union in distal radius fracture patients.

Novadip Biosciences

Novadip BiosciencesVIVES fund

vivesfund.comFEB 14, 2025

FEB 14, 2025

Investment

Generare raised €5M to accelerate discovery of new drugs and molecules hidden in microbes.

Generare

Generare VIVES fund

vivesfund.comDEC 17, 2024

DEC 17, 2024

Milestone

Eligo Bioscience welcomed genetic-medicine leader Bobby Gaspar as board chairman and strengthened its investor syndicate.

Eligo Bioscience

Eligo Bioscience VIVES fund

vivesfund.comDEC 17, 2024

DEC 17, 2024

Investment

BiocSol raised €5.2M in seed funding to develop next-generation microbe-inspired crop-protection solutions, targeting €10M total.

BiocSol

BiocSolVIVES fund

vivesfund.comNOV 20, 2024

NOV 20, 2024

New Fund

VIVES Inter-University Fund closed a second round, raising total fund size to €70M with the European Investment Fund as lead backer.

VIVES Inter-University Fund second closing (€70M)

VIVES fund

vivesfund.comJAN 30, 2024

JAN 30, 2024

Milestone

Portfolio company LMO Space partnered with In-Space Missions, a BAE Systems subsidiary, on the AUREA space domain awareness program.

LMO Space

LMO Space VIVES fund

vivesfund.comSEP 13, 2023

SEP 13, 2023

Page 1 of 2